Tecentriq first front-line extensive-stage SCLC therapy in decades

FDA's approval late Monday of Roche's Tecentriq atezolizumab as front-line treatment for extensive-stage small cell lung cancer marks the first approval of a PD-1/PD-L1 inhibitor in the indication.

Read the full 280 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE